Search
Erasca Inc
ERASAdd to Watchlist
18.150USD
-0.530-2.84%
Close 07-31 16:00（ET）Quotes delayed by 15 min
5.16BMarket Cap
LossP/E TTM
More Details of Erasca Inc Company
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Erasca Inc Info
Ticker SymbolERAS
Company nameErasca Inc
IPO dateJul 15, 2021
CEOLim (Jonathan E)
Number of employees103
Security typeOrdinary Share
Fiscal year-endJul 15
Address3115 Merryfield Row
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18584656511
Websitehttps://www.erasca.com/
Ticker SymbolERAS
IPO dateJul 15, 2021
CEOLim (Jonathan E)
Company Executives of Erasca Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
19.46M
--
Mr. Alexander W. (Alex) Casdin
Mr. Alexander W. (Alex) Casdin
Independent Director
Independent Director
667.72K
--
Dr. James Arthur Bristol
Dr. James Arthur Bristol
Lead Independent Director
Lead Independent Director
207.50K
--
Mr. Ebun S. Garner, J.D.
Mr. Ebun S. Garner, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
25.08K
--
Dr. David M. Chacko, M.D.
Dr. David M. Chacko, M.D.
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
Dr. Julie Hambleton, M.D.
Dr. Julie Hambleton, M.D.
Independent Director
Independent Director
--
--
Dr. Valerie Harding-Start, Ph.D.
Dr. Valerie Harding-Start, Ph.D.
Independent Director
Independent Director
--
--
Dr. Pratik S. Multani, M.D.
Dr. Pratik S. Multani, M.D.
Independent Director
Independent Director
--
--
Dr. Michael David Varney, Ph.D.
Dr. Michael David Varney, Ph.D.
Director, Chair of Research and Development and Scientific Advisory Board member
Director, Chair of Research and Development and Scientific Advisory Board member
--
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
19.46M
--
Mr. Alexander W. (Alex) Casdin
Mr. Alexander W. (Alex) Casdin
Independent Director
Independent Director
667.72K
--
Dr. James Arthur Bristol
Dr. James Arthur Bristol
Lead Independent Director
Lead Independent Director
207.50K
--
Mr. Ebun S. Garner, J.D.
Mr. Ebun S. Garner, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
25.08K
--
Dr. David M. Chacko, M.D.
Dr. David M. Chacko, M.D.
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
Dr. Julie Hambleton, M.D.
Dr. Julie Hambleton, M.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Erasca Inc?
The top five shareholders of Erasca Inc are: Dr. Jonathan E. Lim, M.D.
How many institutions hold shares of Erasca Inc (ERAS)?
As of 2026Q1, 333 institutions hold shares of Erasca Inc, with a combined market value of approximately 240.06M, accounting for 77.62% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -10457676.00.